Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
This document updates the recommendations on the management of Philadelphia
chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs) published in 2011 by …
chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs) published in 2011 by …
“Do we know jack” about JAK? A closer look at JAK/STAT signaling pathway
E Bousoik, H Montazeri Aliabadi - Frontiers in oncology, 2018 - frontiersin.org
Janus tyrosine kinase (JAK) family of proteins have been identified as crucial proteins in
signal transduction initiated by a wide range of membrane receptors. Among the proteins in …
signal transduction initiated by a wide range of membrane receptors. Among the proteins in …
[HTML][HTML] JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
JAK inhibitors have been developed following the discovery of the JAK2V617F in 2005 as
the driver mutation of the majority of non-BCR-ABL1 myeloproliferative neoplasms (MPNs) …
the driver mutation of the majority of non-BCR-ABL1 myeloproliferative neoplasms (MPNs) …
[PDF][PDF] Myelofibrosis: clinicopathologic features, prognosis, and management
JM O'Sullivan, CN Harrison - Clin Adv Hematol Oncol, 2018 - hematologyandoncology.net
Myelofibrosis: Clinicopathologic Features, Prognosis, and Management Page 1 Clinical
Advances in Hematology & Oncology Volume 16, Issue 2 February 2018 121 Myelofibrosis …
Advances in Hematology & Oncology Volume 16, Issue 2 February 2018 121 Myelofibrosis …
Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation
BC Betts, D Bastian, S Iamsawat… - Proceedings of the …, 2018 - National Acad Sciences
Janus kinase 2 (JAK2) signal transduction is a critical mediator of the immune response.
JAK2 is implicated in the onset of graft-versus-host disease (GVHD), which is a significant …
JAK2 is implicated in the onset of graft-versus-host disease (GVHD), which is a significant …
Biodegradable nanoparticles mediated co-delivery of erlotinib (ELTN) and fedratinib (FDTN) toward the treatment of ELTN-resistant non-small cell lung cancer …
D Chen, F Zhang, J Wang, H He, S Duan… - Frontiers in …, 2018 - frontiersin.org
Background: Erlotinib (ELTN)-based targeted therapy as first-line treatment for epidermal
growth factor receptor (EGFR)-mutant lung cancers suffers from insufficient selectivity, side …
growth factor receptor (EGFR)-mutant lung cancers suffers from insufficient selectivity, side …
Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms
J Berdeja, F Palandri, MR Baer, D Quick, JJ Kiladjian… - Leukemia research, 2018 - Elsevier
Abstract Background The Philadelphia chromosome-negative myeloproliferative neoplasms
(MPNs) are associated with increases in janus kinase 2 (JAK2) signaling, often resulting …
(MPNs) are associated with increases in janus kinase 2 (JAK2) signaling, often resulting …
The role of JAK2 inhibitors in MPNs 7 years after approval
F Passamonti, M Maffioli - Blood, The Journal of the American …, 2018 - ashpublications.org
Myeloproliferative neoplasms (MPNs) include essential thrombocythemia, polycythemia
vera (PV), and primary myelofibrosis (MF). Phenotype-driver mutations of JAK2, CALR, and …
vera (PV), and primary myelofibrosis (MF). Phenotype-driver mutations of JAK2, CALR, and …
Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response
X Luo, Z Xu, B Li, T Qin, P Zhang, H Zhang… - Blood cancer …, 2018 - nature.com
Low-dose thalidomide and prednisone alone or combined are effective therapies in some
persons with primary myelofibrosis (PMF) and anemia with or with RBC transfusion …
persons with primary myelofibrosis (PMF) and anemia with or with RBC transfusion …
How I treat myelofibrosis after failure of JAK inhibitors
A Pardanani, A Tefferi - Blood, The Journal of the American …, 2018 - ashpublications.org
The introduction of JAK inhibitors, leading to regulatory approval of ruxolitinib, represents a
major therapeutic advance in myelofibrosis (MF). Most patients experience reduction in …
major therapeutic advance in myelofibrosis (MF). Most patients experience reduction in …